

UTILITY PATENT APPLICATION
TRANSMITTAL

(for new nonprovisional applications under 37 CFR 1.53(b))

"EXPRESS MAIL CERTIFICATE"

02-11-02 Attorney Docket No.

First Named Inventor

P31731X1C1

Anders, et al.

"EXPRESS MAIL" MAILING LABEL NUMBER **EV000523682US** DATE OF DEPOSIT: **08 February 2002**

I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to The Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.


NAME OF PERSON MAILING PAPER OR FEE
(TYPE OR PRINT) *Elsa Matos*

SIGNATURE

*Elsa Matos*11017 U.S. PRO
11010/07138
02/08/02

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. <u>19-2570</u>		7. <input checked="" type="checkbox"/> The Title of the Invention: Isolated 5R Clavams and Methods for Their Manufacture										
<input checked="" type="checkbox"/> General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) <i>(Submit an original, and a duplicate for fee processing)</i>		8. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission from Appln. Serial No. 09/018,806 filed 04 February 1998. <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies d. <input checked="" type="checkbox"/> Use the identical computer-readable form filed in Application No. <u>09/018,806</u>, filed <u>February 4, 1998</u> as the computer-readable form for the instant application. (37 CFR 1.821(e)) 										
2. <input checked="" type="checkbox"/> The total fee is calculated as shown below: <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Basic Filing fee</td> <td style="width: 60%;">\$740.00</td> </tr> <tr> <td>Total Claims 7 - 20 = 0 x \$18</td> <td>\$ 0.00</td> </tr> <tr> <td>Independent Claims 3 - 3 = 0 x \$84</td> <td>\$ 0.00</td> </tr> <tr> <td>Multiple Dependent Claim present. \$280</td> <td></td> </tr> <tr> <td>TOTAL FILING FEE</td> <td>\$740.00</td> </tr> </table>		Basic Filing fee	\$740.00	Total Claims 7 - 20 = 0 x \$18	\$ 0.00	Independent Claims 3 - 3 = 0 x \$84	\$ 0.00	Multiple Dependent Claim present. \$280		TOTAL FILING FEE	\$740.00	9. <input checked="" type="checkbox"/> ACCOMPANYING APPLICATION PARTS <ul style="list-style-type: none"> a. <input type="checkbox"/> Information Disclosure Statement (IDS) b. <input type="checkbox"/> PTO-1449 c. <input type="checkbox"/> Copies of all IDS Citations
Basic Filing fee	\$740.00											
Total Claims 7 - 20 = 0 x \$18	\$ 0.00											
Independent Claims 3 - 3 = 0 x \$84	\$ 0.00											
Multiple Dependent Claim present. \$280												
TOTAL FILING FEE	\$740.00											
3. <input type="checkbox"/> Cancel in this application original claims <u>1</u> to <u>37</u> of the prior application before calculating the filing fee.		10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))										
4. <input checked="" type="checkbox"/> Charge \$740.00 to the above indicated Deposit Account.		11. <input checked="" type="checkbox"/> Prior Application is Assigned to: <u>SmithKline Beecham p.l.c. and</u> <u>The Governors of the University of Alberta</u> <i>(for continuation/divisional with Box 17a completed)</i>										
5. <input checked="" type="checkbox"/> Specification excluding Drawings [Total Pages] <u>33</u>		12. <input checked="" type="checkbox"/> Preliminary Amendment [2]										
<input checked="" type="checkbox"/> Abstract on a separate sheet [Total Pages] <u>1</u>		13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>										
<input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] <u>16</u>		14. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>										
6. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Pages] <u>3</u> <ul style="list-style-type: none"> a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17a completed)</i> c. <input type="checkbox"/> Unsigned Declaration <i>[Note Box 6 below]</i> <ul style="list-style-type: none"> i. <input type="checkbox"/> DELETION OF INVENTOR(S) 		15. <input checked="" type="checkbox"/> Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. <u>09/018,806</u> filed <u>February 4, 1998</u> . A PTO-1449 listing the references is enclosed.										
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).		16. <input type="checkbox"/> Other: _____										
7. <input checked="" type="checkbox"/> Incorporation By Reference <i>(useable if Box 5b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.												
17. <input checked="" type="checkbox"/> Priority Information, check appropriate box and supply the requisite information <ul style="list-style-type: none"> a. The accompanying application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: <u>09/018,806</u> filed <u>February 4, 1998</u>. b. <input type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. filed . c. <input checked="" type="checkbox"/> Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78) This is a continuation of application Serial No. <u>09/018,806</u> filed <u>04 February 1998</u>, which claims priority of Great Britain Application GB 9702218.0 filed <u>04 February 1997</u>. 												
Correspondence Address:	GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939	Respectfully Submitted,  Zoltan Kerekes										
Telephone	(610) 270-5024 Fax (610) 270-5090	Signature Name Registration No. 38,938										

20462

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON, D.C. 20231,

ON 21 AUGUST 1998

~~AGENT/ATTORNEY FOR APPLICANT~~

Aug 21 1998
DATE

11017 U.S. PTO
10/07/1338
02/08/02

Attorney Docket No.: P31731

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Barton et al. August 21, 1998

Serial No.: 09/018,806 Group Art Unit No.: 1652

Filed: February 4, 1998 Examiner: B. Mayhew

For: "Novel Compounds"

**AMENDMENT, STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825**

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Please insert the sequence listing sheets filed herewith after page 30 of the specification and renumber the specification accordingly.


- (X) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.
- (X) I hereby state that the submission filed in accordance with 37 CFR §1.821 (g) does not include new matter.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821 (h) does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with 37 CFR §1.825 (a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

Serial No.: 09/018,806
Group Art Unit No.: 1652

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), is identical to that originally filed.

Respectfully submitted,



Zoltan Kerekes
Attorney for Applicants
Registration No. 38,938

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5024
Facsimile (610) 270-5090
N:\ZK\APPS\P3173\TSEQUEN.DOC